Analysts have been eager to weigh in on the Healthcare sector with new ratings on Liquidia Technologies (LQDA – Research Report), TELA Bio (TELA – Research Report) and Smith & Nephew Snats (SNN – Research Report).
Liquidia Technologies (LQDA)
BTIG analyst Julian Harrison maintained a Buy rating on Liquidia Technologies yesterday and set a price target of $18.00. The company’s shares closed last Thursday at $7.16.
According to TipRanks.com, Harrison is a 1-star analyst with an average return of
Currently, the analyst consensus on Liquidia Technologies is a Moderate Buy with an average price target of $12.33.
See the top stocks recommended by analysts >>
TELA Bio (TELA)
Canaccord Genuity analyst Caitlin Cronin maintained a Buy rating on TELA Bio yesterday and set a price target of $10.00. The company’s shares closed last Thursday at $5.21, close to its 52-week low of $4.23.
According to TipRanks.com, Cronin is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TELA Bio with a $13.50 average price target.
Smith & Nephew Snats (SNN)
Canaccord Genuity analyst William Plovanic maintained a Hold rating on Smith & Nephew Snats yesterday and set a price target of $32.00. The company’s shares closed last Thursday at $25.95.
According to TipRanks.com, Plovanic has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Smith & Nephew Snats with a $32.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LQDA:
